Zwicker, S.; Lira-Junior, R.; Höög, C.; Almer, S.; Boström, E.A.
Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study. Int. J. Mol. Sci. 2017, 18, 1827.
https://doi.org/10.3390/ijms18081827
AMA Style
Zwicker S, Lira-Junior R, Höög C, Almer S, Boström EA.
Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study. International Journal of Molecular Sciences. 2017; 18(8):1827.
https://doi.org/10.3390/ijms18081827
Chicago/Turabian Style
Zwicker, Stephanie, Ronaldo Lira-Junior, Charlotte Höög, Sven Almer, and Elisabeth A. Boström.
2017. "Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study" International Journal of Molecular Sciences 18, no. 8: 1827.
https://doi.org/10.3390/ijms18081827
APA Style
Zwicker, S., Lira-Junior, R., Höög, C., Almer, S., & Boström, E. A.
(2017). Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study. International Journal of Molecular Sciences, 18(8), 1827.
https://doi.org/10.3390/ijms18081827